BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny, Valerya Semenisty, Teresa Macarulla, Erkut Borazanci, Brian M. Wolpin, Salomon M. Stemmer, Talia Golan, Ravit Geva, Mitesh J. Borad, Katrina S. Pedersen, Joon Oh Park, Robert A. Ramirez, David Gutiérrez Abad, Jaime Feliú, Andrés Muñoz, Mariano Ponz‐Sarvisé, Amnon Peled, Tzipora M Lustig, Osnat Bohana‐Kashtan, Stephen M. Shaw, Ella Sorani, Marya Chaney, Shaul Kadosh, Abi Vainstein Haras, Daniel D. Von Hoff, Manuel Hidalgo
Topics & Concepts
PembrolizumabMedicinePopulationInternal medicineOncologyChemotherapyPancreatic cancerCohortCancerImmunologyGastroenterologyImmunotherapyEnvironmental healthPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersPhagocytosis and Immune Regulation